Inhibikase Posts Wider Loss in Q2

Inhibikase Therapeutics (NASDAQ:IKT) released its earnings for the quarter ended June 30, 2025 on August 14, 2025. The company reported a GAAP net loss per share of $0.11, wider than the analyst expectation of a GAAP loss of $0.08 per share. There was no revenue as the company remains pre-commercialization. Expenses rose sharply due to pipeline investments and acquisition effects, leading to a GAAP net loss of $9.9 million, up from $5.0 million in Q2 2024. However, it ended the period with $87.7 million in cash and securities but highlighted ongoing pressures from rising operating costs as the company advances its late-stage clinical trial program. Source: Analyst estimates for the quarter provided by FactSet. Inhibikase Therapeutics pursues new therapies for serious diseases like Parkinson's Disease and pulmonary arterial hypertension (PAH).Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool